RCS - PureTech Health PLC - PRTC's Seaport Appoints Seasoned Execs to Team

Puretech HealthAnnouncement

18/06/2024 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240618:nRSR8450Sa&default-theme=true

RNS Number : 8450S  PureTech Health PLC  18 June 2024

 

18 June 2024

PureTech Health plc

 

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to
Management Team

 

Antony Loebel, M.D., CNS drug development expert and former CEO and CMO at
Sunovion Pharmaceuticals, appointed as Seaport's Chief Medical Officer and
President of Clinical Development

 

Lana Gladstein, J.D., experienced attorney across all legal matters, including
corporate governance, M&A transactions, alliance management and
intellectual property, joins Seaport as General Counsel

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted
that its Founded Entity, Seaport Therapeutics (https://seaporttx.com/) , a
biopharmaceutical company that is advancing novel neuropsychiatric medicines
with a proven strategy and team, today announced it has expanded its executive
team with the appointment of Antony Loebel, M.D., as Chief Medical Officer and
President of Clinical Development, and Lana Gladstein, J.D., as General
Counsel.

 

Dr. Loebel was most recently the President and Chief Executive Officer of
Sunovion Pharmaceuticals, a global pharmaceutical company focused on CNS drug
development and commercialization, from 2019 to 2023. He served as the
company's Chief Medical Officer from 2011 to 2019. Dr. Loebel was instrumental
in the growth of Sunovion from a small to mid-size company with over $2.5
billion in net revenue. He played a key role in the development and
commercialization of LATUDA® for the treatment of patients with bipolar
depression and schizophrenia, with the product achieving commercial success in
the U.S. and globally under his leadership. Other products developed and
approved under Dr. Loebel's leadership included APTIOM® for partial-onset
seizures and KYNMOBI® for the treatment of "OFF" episodes in patients with
Parkinson's disease. Prior to Sunovion, Dr. Loebel's industry experience
included drug development and medical affairs roles at Dainippon Sumitomo
Pharma America and Pfizer, Inc. A board-certified psychiatrist, Dr. Loebel is
a Fellow of the American College of Neuropsychopharmacology and a Life Fellow
of the American Psychiatric Association. He has received multiple recognitions
and awards including the International Society of CNS Drug Development's 20th
Anniversary Award for a consistent track record of innovation and leadership
in CNS drug development in 2022. He was also named to PharmaVOICE's list of
"100 Most Inspiring People" in 2013 and 2019. He received his M.D. from the
University of Washington School of Medicine.

 

Lana Gladstein joins Seaport as General Counsel with over two decades of legal
expertise, including corporate governance, navigating M&A transactions,
licensing and partnerships, and intellectual property matters. Most recently,
she was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage
company developing therapeutics and diagnostics for neurodegenerative
diseases. Her prior roles include Chief Legal Officer at Recipharm (Americas),
Chief Legal Officer and General Counsel at Arranta Bio (acquired by
Recipharm), and Executive Vice President, General Counsel and Officer at
Brammer Bio, (acquired by Thermo Fisher for $1.7 billion). Prior to Brammer
Bio, Ms. Gladstein was a partner at Pepper Hamilton (now Troutman Pepper) and
Nutter, and held previous positions at Goodwin and Nixon Peabody, where she
advised life science companies on corporate and intellectual property
matters. She holds a J.D. from Northeastern University School of Law and a
B.A. in biology from Brandeis University.

 

The full text of the announcement from Seaport is as follows:

 

Seaport Therapeutics Appoints Seasoned Executives to Management Team

 

Antony Loebel, M.D., CNS drug development expert and former CEO and CMO at
Sunovion Pharmaceuticals, appointed as Seaport's Chief Medical Officer and
President of Clinical Development

 

Lana Gladstein, J.D., experienced attorney across all legal matters, including
corporate governance, M&A transactions, alliance management and
intellectual property, joins Seaport as General Counsel

 

BOSTON, June 18, 2024 - Seaport Therapeutics (https://seaporttx.com/) , a
clinical-stage biopharmaceutical company that is advancing novel
neuropsychiatric medicines with a proven strategy and team, today announced it
has expanded its executive team with the appointment of Antony Loebel, M.D.,
as Chief Medical Officer and President of Clinical Development, and Lana
Gladstein, J.D., as General Counsel. Seaport's senior leadership team also
includes Steven M. Paul, M.D., Founder and Chair of the Board of Directors;
Daphne Zohar, Founder, Chief Executive Officer and Board Member; Eric Green,
MBA, Chief Operating Officer; and Michael Chen, Ph.D., Co-founder and Chief
Scientific Officer.

 

"I'm delighted to welcome two more outstanding members to our senior executive
team. As we design and run studies to advance our clinical-stage pipeline of
novel therapeutics focused on important mental health conditions, Tony's deep
understanding of neuropsychiatric drug development builds on our team's
distinct advantages," said Daphne Zohar, Founder and Chief Executive Officer
of Seaport. "We are rapidly growing our company and Lana's experience across
all facets of legal, including corporate governance, transactions, and IP,
will be an important resource to Seaport. I'm thrilled to have both Tony and
Lana onboard."

 

Dr. Loebel was most recently the President and Chief Executive Officer of
Sunovion Pharmaceuticals, a global pharmaceutical company focused on CNS drug
development and commercialization, from 2019 to 2023. He served as the
company's Chief Medical Officer from 2011 to 2019. Dr. Loebel was instrumental
in the growth of Sunovion from a small to mid-size company with over $2.5
billion in net revenue. He played a key role in the development and
commercialization of LATUDA® for the treatment of patients with bipolar
depression and schizophrenia, with the product achieving commercial success in
the U.S. and globally under his leadership. Other products developed and
approved under Dr. Loebel's leadership included APTIOM® for partial-onset
seizures and KYNMOBI® for the treatment of "OFF" episodes in patients with
Parkinson's disease. Prior to Sunovion, Dr. Loebel's industry experience
included drug development and medical affairs roles at Dainippon Sumitomo
Pharma America and Pfizer, Inc. A board-certified psychiatrist, Dr. Loebel is
a Fellow of the American College of Neuropsychopharmacology and a Life Fellow
of the American Psychiatric Association. He has received multiple recognitions
and awards including the International Society of CNS Drug Development's 20th
Anniversary Award for a consistent track record of innovation and leadership
in CNS drug development in 2022. He was also named to PharmaVOICE's list of
"100 Most Inspiring People" in 2013 and 2019. He received his M.D. from the
University of Washington School of Medicine.

 

"I'm excited to join Daphne, Steve and the rest of the incredible team at
Seaport to help further advance its robust pipeline of important
neuropsychiatric medicines," said Dr. Loebel. "We have a unique opportunity to
make a meaningful difference for the millions of people struggling with
serious mental health conditions, including depression and anxiety."

 

Lana Gladstein joins Seaport as General Counsel with over two decades of legal
expertise, including corporate governance, navigating M&A transactions,
licensing and partnerships, and intellectual property matters. Most recently,
she was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage
company developing therapeutics and diagnostics for neurodegenerative
diseases. Her prior roles include Chief Legal Officer at Recipharm (Americas),
Chief Legal Officer and General Counsel at Arranta Bio (acquired by
Recipharm), and Executive Vice President, General Counsel and Officer at
Brammer Bio, (acquired by Thermo Fisher for $1.7 billion). Prior to Brammer
Bio, Ms. Gladstein was a partner at Pepper Hamilton (now Troutman Pepper) and
Nutter, and held previous positions at Goodwin and Nixon Peabody, where she
advised life science companies on corporate and intellectual property
matters. She holds a J.D. from Northeastern University School of Law and a
B.A. in biology from Brandeis University.

 

"I am humbled and thrilled to be joining the team at Seaport," said Ms.
Gladstein. "This is a team with an incredible track record of achievement and
an unwavering commitment to advancing innovative therapeutics for patients. I
look forward to leveraging my experience to build upon Seaport's strong legal
foundation and support its continued growth."

 

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing
the development of novel neuropsychiatric medicines in areas of high unmet
patient needs. The Company has a proven strategy of advancing clinically
validated mechanisms previously held back by limitations that are overcome
with its proprietary Glyph(TM) technology platform. All the therapeutic
candidates in its pipeline of first and best-in-class medicines are based on
the Glyph platform, which is uniquely designed to enable oral bioavailability,
bypass first-pass metabolism and reduce hepatotoxicity and other side effects.
Seaport is led by an experienced team that invented and advanced important
neuropsychiatric medicines and are guided by an extensive network of renowned
scientists, clinicians and key opinion leaders. For more information, please
visit www.seaporttx.com (http://www.seaporttx.com) .

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to Seaport's development plans and
our future prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to known and
unknown risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially from current
expectations, including, but not limited to, those risks, uncertainties and
other important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2023, filed with
the SEC and in our other regulatory filings. These forward-looking statements
are based on assumptions regarding the present and future business strategies
of the Company and the environment in which it will operate in the future.
Each forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we disclaim
any obligation to update or revise these forward-looking statements, whether
as a result of new information, future events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

 

US Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com
(mailto:nichole@tenbridgecommunications.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRALVLBFZQLFBBQ